Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22;12(12):e12217.
doi: 10.7759/cureus.12217.

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol

Affiliations

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol

Günther Krumpl et al. Cureus. .

Abstract

Background and objective This study involved an investigation into the pharmacokinetic and pharmacodynamic behavior of esmolol in the presence of dobutamine in healthy subjects of European ancestry. Methods We conducted a single-center, prospective randomized study of 16 healthy subjects with each receiving an infusion of dobutamine sufficient to increase heart rate (HR) by 30 beats per minute (bpm) followed by a 60-minute infusion of 50 µg/kg/min esmolol. Pharmacokinetics, HR, and blood pressure were evaluated for 180 minutes. Results In the presence of dobutamine, esmolol elimination was substantially faster than without dobutamine, Esmolol infusion reduced dobutamine-induced elevation of HR reversibly whereas the dobutamine-induced systolic blood pressure (SBP) reduction did not recover after the termination of the esmolol infusion. No serious adverse events (AEs) were observed. Conclusions The accelerated elimination of esmolol was likely due to higher cleavage through tissue esterases induced by dobutamine-induced increased tissue passage cycles per time unit. The HR effect was characteristic of a beta-blocker, whereas the blood pressure effect was likely due to a mechanism other than direct beta-blockade. HR remained elevated after the infusion of esmolol and dobutamine, most likely due to persistent blood pressure reduction.

Keywords: cardioselective β-blocker; dobutamine; esmolol; pharmacodynamics; pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Time course of esmolol concentrations in whole blood in the presence and absence of dobutamine
Open squares and solid line: infusion of esmolol (50 µg/kg/min) on top of continuous dobutamine infusion; open circles and broken line: infusion of esmolol (50 µg/kg/min) only [8]. Please note that the elimination phase is lacking for the esmolol-only experiment, because infusion was continued at higher doses for an additional 23 hours
Figure 2
Figure 2. Time course of heart rate, and systolic and diastolic blood pressure
Open squares and solid line: heart rate; open diamonds and broken line: systolic blood pressure; open circles and dotted line: diastolic blood pressure BL: baseline

Similar articles

References

    1. Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D. https://europepmc.org/article/med/7612051. Arzneim-Forsch/Drug Res. 1995;45:536–541. - PubMed
    1. The negative inotropic effect of esmolol on isolated cardiac muscle. Arlock P, Wohlfart B, Sjöberg T, Steen S. Scand Cardiovasc J. 2005;39:250–254. - PubMed
    1. Esmolol inhibits Na+ current in rat ventricular myocytes. Deng CY, Lin SG, Zhang WC, et al. Methods Find Exp Clin Pharmacol. 2006;28:697–702. - PubMed
    1. Esmolol cardioplegia: the cellular mechanism of diastolic arrest. Fallouh HB, Bardswell SC, McLatchie LM, Shattock MJ, Chambers DJ, Kentish JC. Cardiovasc Res. 2010;87:552–560. - PubMed
    1. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. Shibata S, Okamoto Y, Endo S, Ono K. J Pharmacol Sci. 2012;118:255–265. - PubMed

LinkOut - more resources